[
    [
        {
            "time": "",
            "original_text": "君实开盘市值破1500亿！采用“新主流”估值，65亿研发投入的百济为何不敌恒瑞、信达、贝达们？",
            "features": {
                "keywords": [
                    "君实",
                    "市值",
                    "1500亿",
                    "新主流估值",
                    "百济",
                    "恒瑞",
                    "信达",
                    "贝达",
                    "研发投入"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "君实开盘市值破1500亿！采用“新主流”估值，65亿研发投入的百济为何不敌恒瑞、信达、贝达们？",
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 7,
                "Time_Proximity": 9,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        }
    ]
]